BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Alcon  Laboratories  (UK)  Ltd.  submitted  on  18  December  2006  an  application  for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  NEVANAC,  through  the 
centralised  procedure  under  Article  3(2)  (a)  of  Regulation  (EC)  No  726/2004.  The  eligibility  to  the 
centralised procedure was agreed upon by the EMEA/CHMP on 27 June 2007.  
The legal basis for this application refers to:  
A - Centralised / Article 8(3) / New active substance. 
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
Licensing status: 
NEVANAC has been given a Marketing Authorisation in the following countries outside the EEA: 
USA 
Argentina 
Aruba 
Chile 
Guatemala 
Kenya 
Mexico 
Nicaragua 
Surinam 
Trinidad and Tobago 
Uruguay 
Venezuela 
19 August 2005 
19 January 2006 
31 January 2006 
31 March 2006 
19 July 2006 
01 November 2006 
26 September 2006 
06 September 2006 
05 January 2006 
17 January 2006 
04 October 2006 
17 August 2006 
A new application was filed in the following countries:  
New Zealand 
Brazil 
China 
Columbia 
Costa Rica 
Dominican Republic 
El Salvador 
Honduras 
Hong Kong 
Kuwait 
Panama 
Paraguay 
Serbia 
Taiwan 
Thailand 
Turkey 
United Arab Emirates 
Vietnam 
22 May 2006 
30 September 2005 
31 March 2006 
01 August 2005 
30 June 2006 
20 September 2006 
21 August 2006 
17 May 2006 
23 September 2005 
28 November 2005 
19 July 2006 
13 November 2006 
12 December 2005 
31 January 2006 
19 December 2005 
17 November 2006 
23 April 2006 
07 October 2006 
@EMEA 2007 
1/2 
 
 
 
 
 
 
 
 
 
 
 
 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: Gonzalo Calvo Rojas Co-Rapporteur: Steffen Thirstrup  
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 18 December 2006. 
The procedure started on 24 January 2007.  
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  18  April 
2007  (Annex  1).  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 17 April 2007.  
During  the  meeting  on  21-24  May  2007,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 24 May 2007. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  5  July 
2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 29 August 2007. 
During the CHMP meeting on 17-20 September 2007, the CHMP agreed on a list of outstanding 
issues to be addressed in writing and by the applicant. 
The  applicant  submitted  written  explanations  to  the  CHMP  List  of  Outstanding  Issues  on  20 
September 2007. 
The  Rapporteurs  circulated  the  Joint  Assessment  Report  on  the  CHMP  List  of  Outstanding 
Issues to all CHMP members on 8 October 2007. 
During  the  meeting  on  16-18  October  2007,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting  a  Marketing  Authorisation  for  NEVANAC  on  18  October  2007.  The  applicant 
provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation 
on 10 October 2007. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 11 December 2007. 
@EMEA 2007 
2/2 
 
 
 
 
 
 
 
